Advances in stem cell transplantation from EBMT 2026: managing GvHD, donor selection & evolving clinical strategies

This episode reviews major advances presented at the EBMT 2026 meeting in Madrid, covering novel treatments for acute and chronic GVHD, including a promising microbiome-based therapy, and new targeted agents. Experts discuss the growing importance of donor germline genetics, updated guidance for Hodgkin lymphoma transplantation, the shifting role of CAR T‑cell therapy in non‑Hodgkin lymphoma, and how measurable residual disease (MRD) is shaping transplant decisions and post‑transplant care. Overall, the episode highlights how these developments are improving personalization and outcomes in haemopoietic stem cell transplantation.